DNA甲基化在外周T细胞淋巴瘤中的研究进展
Advances in DNA Methylation in Peripheral T Cell Lymphoma
DOI: 10.12677/acm.2024.1482338, PDF,   
作者: 张向慧：天水市第一人民医院血液病科，甘肃 天水
关键词: 外周T细胞淋巴瘤；DNA甲基化；发病机制；DNMT；TET；IDH；Peripheral T-Cell Lymphoma； DNA Methylation； Mechanism； DNMT； TET； IDH
摘要: 外周T细胞淋巴瘤是一组罕见的强侵袭性的非霍奇金淋巴瘤，绝大部分目前治疗效果欠佳。近些年的证据表明表观遗传失调对于PTCL的发生发展起着驱动作用，特别是DNA甲基化。已发现在PTCL中存在DNA甲基化异常以及DNA甲基化修饰酶DNMT、TET、IDH的频繁突变，且与患者不良预后相关。随着对PTCL基因组学认识的深入，DNA甲基化作为表观遗传学的一个重要组成部分，有望为治疗PTCL提供新方向。
Abstract: Peripheral T-cell lymphoma (PTCL) is a group of rare, aggressive non-Hodgkin’s lymphomas, and most of them have poor treatment outcomes. Recent evidence suggests that epigenetic dysregulation plays a driving role in the occurrence and development of PTCL, especially DNA methylation. Abnormal DNA methylation and frequent mutations of DNA methylation modification enzyme DNMT, TET, and IDH have been found in PTCL, which are associated with poor prognosis of patients. With the deepening understanding of the genomics of PTCL, DNA methylation, as an important component of epigenetics, is expected to provide new directions for the treatment of PTCL.
文章引用：张向慧. DNA甲基化在外周T细胞淋巴瘤中的研究进展[J]. 临床医学进展, 2024, 14(8): 1181-1187. https://doi.org/10.12677/acm.2024.1482338

参考文献

[1] Zhang, P. and Zhang, M. (2020) Epigenetic Alterations and Advancement of Treatment in Peripheral T-Cell Lymphoma. Clinical Epigenetics, 12, Article No. 169. [Google Scholar] [CrossRef] [PubMed]
[2] Swerdlow, S.H., Campo, E., Pileri, S.A., Harris, N.L., Stein, H., Siebert, R., et al. (2016) The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms. Blood, 127, 2375-2390. [Google Scholar] [CrossRef] [PubMed]
[3] Luminari, S. and Skrypets, T. (2021) What’s New in Peripheral T‐cell Lymphomas. Hematological Oncology, 39, 52-60. [Google Scholar] [CrossRef] [PubMed]
[4] Zain, J.M. (2019) Aggressive T‐cell Lymphomas: 2019 Updates on Diagnosis, Risk Stratification, and Management. American Journal of Hematology, 94, 929-946. [Google Scholar] [CrossRef] [PubMed]
[5] Sibon, D. (2022) Peripheral T-Cell Lymphomas: Therapeutic Approaches. Cancers, 14, Article 2332. [Google Scholar] [CrossRef] [PubMed]
[6] Heavican, T.B., Bouska, A., Yu, J., et al. (2019) Genetic Drivers of Oncogenic Pathways in molecular Subgroups of Peripheral T-Cell Lymphoma. Blood, 133, 1664-1676. [Google Scholar] [CrossRef] [PubMed]
[7] Xie, C., Li, X., Zeng, H. and Qian, W. (2020) Molecular Insights into Pathogenesis and Targeted Therapy of Peripheral T Cell Lymphoma. Experimental Hematology & Oncology, 9, Article No. 30. [Google Scholar] [CrossRef] [PubMed]
[8] Lemonnier, F., Gaulard, P. and de Leval, L. (2018) New Insights in the Pathogenesis of T-Cell Lymphomas. Current Opinion in Oncology, 30, 277-284. [Google Scholar] [CrossRef] [PubMed]
[9] Willemsen, M. and Schouten, H.C. (2017) Inappropriate Costimulation and Aberrant DNA Methylation as Therapeutic Targets in Angioimmunoblastic T-Cell Lymphoma. Biomarker Research, 5, Article No. 6. [Google Scholar] [CrossRef] [PubMed]
[10] Epstein-Peterson, Z.D. and Horwitz, S.M. (2021) Molecularly Targeted Therapies for Relapsed and Refractory Peripheral T-Cell Lymphomas. Seminars in Hematology, 58, 78-84. [Google Scholar] [CrossRef] [PubMed]
[11] Liu, M.K., Sun, X.J., Gao, X.D., et al. (2021) Methylation Alterations and Advance of Treatment in Lymphoma. Frontiers in Bioscience, 26, 602-613. [Google Scholar] [CrossRef] [PubMed]
[12] Iqbal, J., Amador, C., McKeithan, T.W. and Chan, W.C. (2018) Molecular and Genomic Landscape of Peripheral T-Cell Lymphoma. Cancer Treatment and Research, 176, 31-68. [Google Scholar] [CrossRef] [PubMed]
[13] Palomero, T., Couronné, L., Khiabanian, H., Kim, M., Ambesi-Impiombato, A., Perez-Garcia, A., et al. (2014) Recurrent Mutations in Epigenetic Regulators, RHOA and FYN Kinase in Peripheral T Cell Lymphomas. Nature Genetics, 46, 166-170. [Google Scholar] [CrossRef] [PubMed]
[14] Dan, J. and Chen, T. (2022) Genetic Studies on Mammalian DNA Methyltransferases. In: Jeltsch, A. and Jurkowska, R.Z., Eds., DNA Methyltransferases—Role and Function, Springer, 111-136. [Google Scholar] [CrossRef] [PubMed]
[15] Meng, W., Wang, Z., Zhang, Y., Hou, Y. and Xue, J. (2024) Epigenetic Marks or Not? The Discovery of Novel DNA Modifications in Eukaryotes. Journal of Biological Chemistry, 300, Article ID: 106791. [Google Scholar] [CrossRef] [PubMed]
[16] Ma, H., O’Connor, O.A. and Marchi, E. (2019) New Directions in Treating Peripheral T-Cell Lymphomas (PTCL): Leveraging Epigenetic Modifiers Alone and in Combination. Expert Review of Hematology, 12, 137-146. [Google Scholar] [CrossRef] [PubMed]
[17] Ruan, J., Moskowitz, A., Mehta-Shah, N., et al. (2023) Multicenter Phase 2 Study of Oral Azacitidine (CC-486) plus CHOP as Initial Treatment for PTCL. Blood, 141, 2194-2205.
[18] Baylin, S.B. and Jones, P.A. (2011) A Decade of Exploring the Cancer Epigenome—Biological and Translational Implications. Nature Reviews Cancer, 11, 726-734. [Google Scholar] [CrossRef] [PubMed]
[19] Kulis, M. and Esteller, M. (2010) DNA Methylation and Cancer. Advances in Genetics, 70, 27-56. [Google Scholar] [CrossRef] [PubMed]
[20] Ko, M., An, J., Pastor, W.A., Koralov, S.B., Rajewsky, K. and Rao, A. (2014) TET Proteins and 5‐methylcytosine Oxidation in Hematological Cancers. Immunological Reviews, 263, 6-21. [Google Scholar] [CrossRef] [PubMed]
[21] Kim, H., Jung, I., Lee, C.H., An, J. and Ko, M. (2023) Development of Novel Epigenetic Anti-Cancer Therapy Targeting TET Proteins. International Journal of Molecular Sciences, 24, Article ID: 16375. [Google Scholar] [CrossRef] [PubMed]
[22] Weissmann, S., Alpermann, T., Grossmann, V., Kowarsch, A., Nadarajah, N., Eder, C., et al. (2011) Landscape of TET2 Mutations in Acute Myeloid Leukemia. Leukemia, 26, 934-942. [Google Scholar] [CrossRef] [PubMed]
[23] Chiba, S. (2016) Dysregulation of TET2 in Hematologic Malignancies. International Journal of Hematology, 105, 17-22. [Google Scholar] [CrossRef] [PubMed]
[24] Scourzic, L., Couronné, L., Pedersen, M.T., Della Valle, V., Diop, M., Mylonas, E., et al. (2016) DNMT3AR882H Mutant and Tet2 Inactivation Cooperate in the Deregulation of DNA Methylation Control to Induce Lymphoid Malignancies in Mice. Leukemia, 30, 1388-1398. [Google Scholar] [CrossRef] [PubMed]
[25] Yao, W., Wu, F., Zhang, W., Chuang, S., Thompson, J.S., Chen, Z., et al. (2020) Angioimmunoblastic T‐Cell Lymphoma Contains Multiple Clonal T‐Cell Populations Derived from a Common TET2 Mutant Progenitor Cell. The Journal of Pathology, 250, 346-357. [Google Scholar] [CrossRef] [PubMed]
[26] de Pádua Covas Lage, L.A., Barreto, G.C., Culler, H.F., Cavalcante, J.B., de Oliveira Alves, L.B., Nardinelli, L., et al. (2022) TET-2 Mutations Predict Poor Outcomes and Are Associated with Unfavorable Clinical-Biological Features in PTCL, Not Otherwise Specified and Angioimmunoblastic T-Cell Lymphoma in Brazilian Patients. Cancer Biomarkers, 35, 179-191. [Google Scholar] [CrossRef] [PubMed]
[27] Lemonnier, F., Couronné, L., Parrens, M., Jaïs, J., Travert, M., Lamant, L., et al. (2012) Recurrent TET2 Mutations in Peripheral T-Cell Lymphomas Correlate with TFH-Like Features and Adverse Clinical Parameters. Blood, 120, 1466-1469. [Google Scholar] [CrossRef] [PubMed]
[28] Muto, H., Sakata-Yanagimoto, M., Nagae, G., Shiozawa, Y., Miyake, Y., Yoshida, K., et al. (2014) Reduced TET2 Function Leads to T-Cell Lymphoma with Follicular Helper T-Cell-Like Features in Mice. Blood Cancer Journal, 4, e264. [Google Scholar] [CrossRef] [PubMed]
[29] Baron, B.W., Anastasi, J., Montag, A., Huo, D., Baron, R.M., Karrison, T., et al. (2004) The Human BCL6 Transgene Promotes the Development of Lymphomas in the Mouse. Proceedings of the National Academy of Sciences of the United States of America, 101, 14198-14203. [Google Scholar] [CrossRef] [PubMed]
[30] López-Moyado, I.F., Tsagaratou, A., Yuita, H., Seo, H., Delatte, B., Heinz, S., et al. (2019) Paradoxical Association of TET Loss of Function with Genome-Wide DNA Hypomethylation. Proceedings of the National Academy of Sciences of the United States of America, 116, 16933-16942. [Google Scholar] [CrossRef] [PubMed]
[31] Sakata-Yanagimoto, M. (2015) Multistep Tumorigenesis in Peripheral T Cell Lymphoma. International Journal of Hematology, 102, 523-527. [Google Scholar] [CrossRef] [PubMed]
[32] Odejide, O., Weigert, O., Lane, A.A., Toscano, D., Lunning, M.A., Kopp, N., et al. (2014) A Targeted Mutational Landscape of Angioimmunoblastic T-Cell Lymphoma. Blood, 123, 1293-1296. [Google Scholar] [CrossRef] [PubMed]
[33] Yang, L., Rau, R. and Goodell, M.A. (2015) DNMT3A in Haematological Malignancies. Nature Reviews Cancer, 15, 152-165. [Google Scholar] [CrossRef] [PubMed]
[34] Robertson, K.D. (2001) DNA Methylation, Methyltransferases, and Cancer. Oncogene, 20, 3139-3155. [Google Scholar] [CrossRef] [PubMed]
[35] Peters, S.L., Hlady, R.A., Opavska, J., Klinkebiel, D., Novakova, S., Smith, L.M., et al. (2013) Essential Role for Dnmt1 in the Prevention and Maintenance of MYC-Induced T-Cell Lymphomas. Molecular and Cellular Biology, 33, 4321-4333. [Google Scholar] [CrossRef] [PubMed]
[36] Haney, S.L., Upchurch, G.M., Opavska, J., Klinkebiel, D., Hlady, R.A., Roy, S., et al. (2016) Dnmt3a Is a Haploinsufficient Tumor Suppressor in CD8+ Peripheral T Cell Lymphoma. PLOS Genetics, 12, e1006334. [Google Scholar] [CrossRef] [PubMed]
[37] Haney, S.L., Upchurch, G.M., Opavska, J., Klinkebiel, D., Appiah, A.K., Smith, L.M., et al. (2016) Loss of Dnmt3a Induces CLL and PTCL with Distinct Methylomes and Transcriptomes in Mice. Scientific Reports, 6, Article No. 34222. [Google Scholar] [CrossRef] [PubMed]
[38] Tian, W., Zhang, W., Wang, Y., Jin, R., Wang, Y., Guo, H., et al. (2022) Recent Advances of IDH1 Mutant Inhibitor in Cancer Therapy. Frontiers in Pharmacology, 13, Article 982424. [Google Scholar] [CrossRef] [PubMed]
[39] Dang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M., et al. (2009) Cancer-Associated IDH1 Mutations Produce 2-Hydroxyglutarate. Nature, 462, 739-744. [Google Scholar] [CrossRef] [PubMed]
[40] Pirozzi, C.J. and Yan, H. (2021) The Implications of IDH Mutations for Cancer Development and Therapy. Nature Reviews Clinical Oncology, 18, 645-661. [Google Scholar] [CrossRef] [PubMed]
[41] Chowdhury, R., Yeoh, K.K., Tian, Y., Hillringhaus, L., Bagg, E.A., Rose, N.R., et al. (2011) The Oncometabolite 2‐Hydroxyglutarate Inhibits Histone Lysine Demethylases. EMBO Reports, 12, 463-469. [Google Scholar] [CrossRef] [PubMed]
[42] Figueroa, M.E., Abdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A., et al. (2010) Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. Cancer Cell, 18, 553-567. [Google Scholar] [CrossRef] [PubMed]
[43] Lu, C., Ward, P.S., Kapoor, G.S., Rohle, D., Turcan, S., Abdel-Wahab, O., et al. (2012) IDH Mutation Impairs Histone Demethylation and Results in a Block to Cell Differentiation. Nature, 483, 474-478. [Google Scholar] [CrossRef] [PubMed]
[44] Cairns, R.A., Iqbal, J., Lemonnier, F., Kucuk, C., de Leval, L., Jais, J., et al. (2012) IDH2 Mutations Are Frequent in Angioimmunoblastic T-Cell Lymphoma. Blood, 119, 1901-1903. [Google Scholar] [CrossRef] [PubMed]
[45] Wang, C., McKeithan, T.W., Gong, Q., Zhang, W., Bouska, A., Rosenwald, A., et al. (2015) IDH2 R172 Mutations Define a Unique Subgroup of Patients with Angioimmunoblastic T-Cell Lymphoma. Blood, 126, 1741-1752. [Google Scholar] [CrossRef] [PubMed]
[46] Lemonnier, F., Cairns, R.A., Inoue, S., Li, W.Y., Dupuy, A., Broutin, S., et al. (2016) The IDH2 R172K Mutation Associated with Angioimmunoblastic T-Cell Lymphoma Produces 2HG in T Cells and Impacts Lymphoid Development. Proceedings of the National Academy of Sciences of the United States of America, 113, 15084-15089. [Google Scholar] [CrossRef] [PubMed]
[47] Cai, M., Cheng, S., Wang, X., Hu, J., Song, Y., Huang, Y., et al. (2020) CEOP/IVE/GDP Alternating Regimen Compared with CEOP as the First-Line Therapy for Newly Diagnosed Patients with Peripheral T Cell Lymphoma: Results from a Phase 2, Multicenter, Randomized, Controlled Clinical Trial. Genome Medicine, 12, Article No. 41. [Google Scholar] [CrossRef] [PubMed]
[48] Cogle, C.R., Scott, B.L., Boyd, T. and Garcia-Manero, G. (2015) Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia. The Oncologist, 20, 1404-1412. [Google Scholar] [CrossRef] [PubMed]
[49] Lee, S., Urman, A. and Desai, P. (2019) Emerging Drug Profile: Krebs Cycle and Cancer: IDH Mutations and Therapeutic Implications. Leukemia & Lymphoma, 60, 2635-2645. [Google Scholar] [CrossRef] [PubMed]
[50] Liu, Y., Wang, C., Li, X., Dong, L., Yang, Q., Chen, M., et al. (2021) Improved Clinical Outcome in a Randomized Phase II Study of Anti-Pd-1 Camrelizumab Plus Decitabine in Relapsed/refractory Hodgkin Lymphoma. Journal for ImmunoTherapy of Cancer, 9, e002347. [Google Scholar] [CrossRef] [PubMed]
[51] Wong, J., Gruber, E., Maher, B., Waltham, M., Sabouri-Thompson, Z., Jong, I., et al. (2022) Integrated Clinical and Genomic Evaluation of Guadecitabine (SGI-110) in Peripheral T-Cell Lymphoma. Leukemia, 36, 1654-1665. [Google Scholar] [CrossRef] [PubMed]

为你推荐